3 min read
The Hidden Value Risk: How Unvalidated IT Stacks Delay Clinical Trials and Slash Biotech Valuation
When biotech founders and finance leaders evaluate corporate valuation, focus naturally gravitates toward asset pipelines, IP portfolios, and...